Short answer: bimatoprost is a prostaglandin analog that prolongs the eyelash growth phase. Latisse is the FDA-approved 0.03% topical solution for hypotrichosis of the eyelashes. Compounded bimatoprost lash serums are prescription products but not FDA-approved finished drugs — with variable concentrations and applicator designs.
Eyelash growth serums occupy a distinct niche within prescription skincare — prostaglandin mechanism, periorbital application, and eye-specific side effects. Here is how FDA-approved Latisse compares to compounded telehealth alternatives.
How Bimatoprost Grows Lashes
Bimatoprost increases the proportion of lashes in anagen (growth phase) and may increase melanogenesis, making lashes longer, thicker, and darker.[1] Effects are reversible after discontinuation — lashes gradually return toward baseline over months.[1] It was originally developed as an ophthalmic glaucoma medication; lash growth was observed as a side effect before cosmetic approval.
Latisse — FDA-Approved Product
Latisse (bimatoprost ophthalmic solution 0.03%) is FDA-approved to treat inadequate eyelashes (hypotrichosis).[1] It is applied once daily to the upper eyelid margin with supplied applicators — not into the eye. Clinical trials demonstrated statistically significant lash improvement vs. vehicle.[1]
Side Effects and Warnings
Common effects include itchy red eyes, skin hyperpigmentation on the eyelid, and dry eye symptoms.[1] Iris pigmentation change (possibly permanent) is a labeled risk if solution repeatedly contacts iris tissue — more relevant to glaucoma drop use but still part of risk counseling.[2] Fat atrophy around the orbit (periorbital hollowing) has been reported with prostaglandin analogs — report contour changes to your prescriber.
Application precision matters: use only at the upper lash line as directed; excess on lower lid or cheek skin can cause unwanted hair growth.[1]
Compounded Bimatoprost Lash Serums
Telehealth programs may prescribe compounded bimatoprost lash formulations — often at different concentrations or with cosmetic vehicle additives. These compounded serums are not FDA-approved finished products.[3] Concentration, sterility, and applicator design may differ from Latisse. Ask for bimatoprost percentage and compounding pharmacy credentials before substituting.
Lash Serums vs. Facial Skincare
Periorbital application introduces ocular exposure risk absent in facial creams. Do not use glaucoma bimatoprost drops as DIY lash serum — concentration and delivery differ. Pregnancy and breastfeeding status should be discussed; Latisse labeling reflects available data.[1]
Bottom Line
Bimatoprost works for lash growth with documented tradeoffs. Latisse is the FDA-reviewed finished product; compounded lash serums require the same pharmacy and prescriber scrutiny as other telehealth skincare. Compare cost, concentration disclosure, and eye side-effect counseling — not influencer before-and-afters alone.
Sources
- Latisse (bimatoprost ophthalmic solution) 0.03% — Prescribing Information — U.S. Food and Drug Administration accessdata.fda.gov
- Bimatoprost — StatPearls ncbi.nlm.nih.gov
- Human Drug Compounding — U.S. Food and Drug Administration fda.gov
Frequently Asked Questions
Do lashes fall out when I stop bimatoprost?
Yes — effects reverse over weeks to months as lashes return toward their prior growth cycle.[1]
Can I use Latisse on eyebrows?
Latisse is FDA-approved for upper eyelid lash margin only. Off-label eyebrow use occurs but lacks the same approval and risk data.[1]
Are compounded lash serums FDA-approved?
No. Compounded bimatoprost products are not FDA-approved finished drug products, even when using the same active molecule.[3]